SCHEMBL6794045

SCHEMBL6794045

CC(C(=O)Nc1ccc(N)cc1)c1ccccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
POLB P06746 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
ALDH1A1 P00352 4/20 0.45
MAPT P10636 4/20 0.45
KDM4E B2RXH2 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
PSEN1 P49768 3/20 0.44
PSEN2 P49810 3/20 0.44
APH1B Q8WW43 3/20 0.44
NCSTN Q92542 3/20 0.44
APH1A Q96BI3 3/20 0.44
PSENEN Q9NZ42 3/20 0.44
TAAR1 Q96RJ0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6801318 0.81 KMT2A (0.55) POLBNPC1RAB9AALDH1A1MAPT
SCHEMBL15551124 0.80 CYP1A2 (0.57) CYP1A2CYP3A4SMN1; SMN2HPGDHSD17B10
SCHEMBL15745601 0.79 CYP1A2 (0.55) CYP1A2CYP3A4SMN1; SMN2HPGDHSD17B10
SCHEMBL21378793 0.79 CYP1A2 (0.55) CYP1A2CYP3A4SMN1; SMN2HPGDHSD17B10
SCHEMBL21378747 0.79 CYP1A2 (0.55) CYP1A2CYP3A4SMN1; SMN2HPGDHSD17B10
SCHEMBL29627913 0.73 CYP1A2 (0.60) CYP1A2CYP3A4SMN1; SMN2POLBALDH1A1
SCHEMBL626825 0.73 CYP1A2 (0.60) CYP1A2CYP3A4SMN1; SMN2POLBALDH1A1
SCHEMBL27536605 0.72 CYP1A2 (0.64) CYP1A2CYP3A4SMN1; SMN2POLBNPC1
SCHEMBL2642376 0.72 CA1 (0.62) CYP1A2SMN1; SMN2HPGDHSD17B10POLB
SCHEMBL3099628 0.72 NPC1 (0.65) SMN1; SMN2NPC1RAB9AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed
CN-1478077-A Benzamide compounds as APO B secretion inhibitors ����ҩƷ��ҵ��ʽ���� 2004-02-25 CN disclosed
EP-1326835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-16 EP disclosed
WO-2002028835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 CYP1A2 640/4885CYP3A4 1229/4885SMN1; SMN2 2504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.